Ernexa Therapeutics Inc.

ERNA Healthcare Biotechnology

Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

2.09 0.08 −3.69%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−70.69
Beneish M
−24.48
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(321.22%) (2,514.66%) (687.80%) 87.78%

+8 more TTM periods

ROA
(176.62%) (146.19%) (253.99%) (264.31%)
ROIC
0.00% 0.00% (1,126.57%) (1,185.59%)
Return on Tangible Assets
(403.22%) (172.08%) (12,368.42%) (1,383.27%)
Average Days of Receivables
0.00 — 0.00 0.00
Free Cash Flow per Share
(7.50) (9.16) (28.03) (29.50)
Free Cash Flow
(8.88) (7.25) (7.07) (9.70)
Other line items

Show all line items

Columns are period end dates